Evaluation of Toxicity Score and Precise Snake Venom Analytics for Next Generation Antivenom Development

下一代抗蛇毒血清开发的毒性评分评估和精确蛇毒分析

基本信息

  • 批准号:
    10394860
  • 负责人:
  • 金额:
    $ 13.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-01 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT The overall goal of this project is to engage undergraduate and graduate students in innovative studies in molecular toxinology that have the potential to contribute to important advances in our understanding of snake venom pathology and the development of novel antibody-based therapeutics. According to WHO statistics, it is estimated that in 2020 there will be 125,000 new deaths world-wide reported due to snake envenomation. In spite of its importance for snake bite envenomation as a neglected tropical disease and global health issue, very little is known of the mechanism of action of snake venom and intrinsic toxic/lethal contribution. The scientific foundation for our study is that a specific combination of snake venom toxins plays a critical role in snakebites by causing necrosis, coagulopathy, severe hemorrhaging and eventually death. Inasmuch as individual toxins have been evaluated, synergistic mechanism for snake venom pathology are lacking and warranted for antidote development. We hypothesize that precise toxicity evaluation and snake venom analytics of crude/fractionated venom and recombinant toxins will provide a model in which priority can be given to the most toxic venom component(s). To test our hypothesis, we will address (3) Specific Aims: Specific Aim 1: To profile snake venom composition, combinational assessment and intrinsic toxicity. We will purify and characterize snake venom of Crotalid snake species. Characterization will include profiling snake venom to identify the toxins in each fraction and abundance. Students will investigate the mechanism of action different combinations of venom fractions. We will characterize the lethal concentrations/doses of each venom fraction on HUVEC cells, blood coagulation, and will validate the toxicity score for each fraction using an in vivo lethality mouse model. Specific Aim 2: To produce recombinant venom peptides. We will clone these toxins from our collection of cDNA libraries and will generate plasmids and transform competent E.coli cells for protein expression and purification. Development of methods to produce recombinant toxins is essential for antivenom development and investigating toxicity and targets for medically relevant venom peptide. These studies will also be essential to use toxins in solving structures to venom toxins or structures in complexes with known targets. Specific Aim 3: To identify snake venom biomarkers in plasma exosomes. We will explore the “venom-reactome” using novel Evtrap technology and proteomics in discovery-based analysis of snake venom biomarkers from mouse plasma exosomes. Comprehensive snake venom biomarker analysis will shed new light on the pathophysiology, metabolic, biological, cellular and immunological responses to snake venom.
摘要 该项目的总体目标是让本科生和研究生参与创新研究, 分子毒理学有可能有助于我们对蛇的理解取得重要进展, 毒液病理学和基于抗体的新疗法的发展。据世卫组织统计, 据估计,到2020年,全世界将有125,000例新的死亡报告是由于蛇的毒液。在 尽管它对于蛇咬伤毒液蛰入作为一种被忽视的热带疾病和全球健康问题的重要性, 人们对蛇毒的作用机制和内在毒性/致命作用知之甚少。的 我们研究的科学基础是,蛇毒毒素的特定组合在 被蛇咬伤后,会引起坏死、凝血功能障碍、严重水肿,最终死亡。只要 个别毒素已被评估,缺乏蛇毒病理学的协同机制, 研发解毒剂我们假设精确的毒性评估和蛇毒 粗/分级毒液和重组毒素的分析将提供一个模型, 可以给予毒性最强的毒液成分。为了验证我们的假设,我们将讨论(3)具体的 目的:具体目的1:分析蛇毒成分、组合评估和内在 毒性我们将纯化和表征响尾蛇蛇毒。表征将包括 分析蛇毒,以确定毒素的每一个部分和丰度。学生将调查 毒液组分的不同组合的作用机制。我们将描述致命的 在HUVEC细胞上的每种毒液级分的浓度/剂量、血液凝固,并将验证毒性 使用体内致死小鼠模型对每个级分进行评分。具体目标2:生产重组体 毒液肽我们将从我们收集的cDNA库中克隆这些毒素并产生质粒 并转化感受态大肠杆菌细胞用于蛋白质表达和纯化。制定方法, 生产重组毒素对于抗蛇毒血清的开发和研究毒性和靶点至关重要。 医学上相关的毒液肽这些研究也将是必不可少的使用毒素在解决结构, 毒液毒素或与已知目标复合的结构。具体目标3:鉴别蛇毒 血浆外泌体中的生物标志物。我们将使用新的Evtrap技术探索“毒液反应组”, 蛋白质组学在小鼠血浆外泌体蛇毒生物标志物的发现分析中的应用。 全面的蛇毒生物标志物分析将揭示新的光的病理生理学,代谢, 对蛇毒的生物、细胞和免疫反应。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Examination of the Efficacy and Cross-Reactivity of a Novel Polyclonal Antibody Targeting the Disintegrin Domain in SVMPs to Neutralize Snake Venom.
  • DOI:
    10.3390/toxins13040254
  • 发表时间:
    2021-03-31
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Szteiter SS;Diego IN;Ortegon J;Salinas EM;Cirilo A;Reyes A;Sanchez O;Suntravat M;Salazar E;Sánchez EE;Galan JA
  • 通讯作者:
    Galan JA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jacob Anthony Galan其他文献

Crotalus lepidus Morulus ) de la roca de Tamaulipas , México
Crotalus lepidus Morulus) de la roca de Tamaulipas, 墨西哥
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Miguel Borja;Jacob Anthony Galan;Esteban Cantu;Alejandro Zugasti;;D. Lazcano;S. Lucena;Montamas Suntravat
  • 通讯作者:
    Montamas Suntravat

Jacob Anthony Galan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Research Grant
Development of CD81 Antibody Therapy for Osteosarcoma - Focused on Exosomes -
骨肉瘤 CD81 抗体疗法的开发 - 专注于外泌体 -
  • 批准号:
    23K08593
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
  • 批准号:
    10761398
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBIR 第一期:通过抗体依赖性细胞介导的自然杀伤细胞的细胞毒性机制,针对急性髓性白血病新抗原的抗体疗法
  • 批准号:
    2246487
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Standard Grant
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
  • 批准号:
    10511223
  • 财政年份:
    2022
  • 资助金额:
    $ 13.8万
  • 项目类别:
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
  • 批准号:
    10643886
  • 财政年份:
    2022
  • 资助金额:
    $ 13.8万
  • 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
  • 批准号:
    10511323
  • 财政年份:
    2022
  • 资助金额:
    $ 13.8万
  • 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
  • 批准号:
    10657706
  • 财政年份:
    2022
  • 资助金额:
    $ 13.8万
  • 项目类别:
Hacking Co-Stimulatory Receptors with Targeted Checkpoint Antibody Therapy
用靶向检查点抗体疗法攻击共刺激受体
  • 批准号:
    574961-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.8万
  • 项目类别:
    University Undergraduate Student Research Awards
Imaging the multifaceted response to a bispecific antibody therapy
双特异性抗体疗法的多方面反应成像
  • 批准号:
    10451574
  • 财政年份:
    2021
  • 资助金额:
    $ 13.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了